Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2005-01-25
2005-01-25
Li, Q. Janice (Department: 1632)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S184100, C424S200100, C424S236100, C424S258100, C424S282100, C424S093200, C435S320100, C435S069100, C435S069700, C514S002600, C514S04400A, C530S350000, C530S387300
Reexamination Certificate
active
06846488
ABSTRACT:
The present invention provides methods of inducing immune responses by recombinant antigen-enterotoxin chimeric mucosal immunogens that contain the A2/B subunits of cholera toxin or heat-labile type II toxins. These chimeric immunogens differentially enhance antibody secretion, cytokine production, as well as B7-dependent co-stimulation of T cells and CD40L expression on CD4+T cells.
REFERENCES:
patent: 5656488 (1997-08-01), Curtiss
patent: 6030624 (2000-02-01), Russell et al.
patent: 6110898 (2000-08-01), Malone et al.
Immune Tolerance, PubMed, Mesh term database 2004.*
Schodel et al. Recognition of a hepatitis B virus nucleocapsid T-cell epitiope expressed as a fusion protein with the subunit B ofEscherichia coliheat labile enterotoxin in attenuated salmonellae 1990.*
Connell et al. Characterization of hybrid toxins produced inescherichia coliby assembly of A and B polypeptides from type I and type II heat-labile enterotoxins vol. 60 No. 4 pp. 1653-1661. Infection and Immunity, 1992.*
Rappuoli, et al.Structure and Mucosal Adjuvanticity of Cholera and Escherichia coli Heat-Labile Interotoxins.vol. 20, 1999, pp. 493-500.
Connell, et al.Immunostimulatory Activity of LT-IIA, A Type II Heat-Labile Enterotoxin of Escherichia coli. Elsevier Science.vol. 62, 1998, pp. 117-120.
Hajishengallis, et al.Mucosal Immunization With a Bacterial Protein Antigen Genetically Coupled to Cholera Toxin A2/B Subunits. The Journal of Immunology,vol. 154, pp. 4322-4332. 1995.
Hajishengallis, et al.Persistence of Serum and Salivary Antibody Responses After Oral Immunization with a Bacterial Protein Antigen Genetically Linked to the A2/B Subunits of Cholera Toxin. Infection and Immunity,vol. 64, pp. 665-667. 1996.
Toida, et al.Oral Immunization With the Saliva-Binding Region of Streptococcus Mutans AGI/II Genetically Coupled to the Cholera Toxin B Subunit Elicits T-Helper-Cell Responses in Gut-Associated Lymphoid Tissues. Infection and Immunity,vol. 65, pp. 909-915. 1997.
Connell Terry D.
Russell Michael W.
Adler Benjamin Aaron
Li Q. Janice
The UAB Research Foundation
LandOfFree
Chimeric antigen-enterotoxin mucosal immunogens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric antigen-enterotoxin mucosal immunogens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric antigen-enterotoxin mucosal immunogens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3375014